Martin Auster
Stock Analyst at Raymond James
(3.85)
# 643
Out of 5,134 analysts
56
Total ratings
53.49%
Success rate
10.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Strong Buy | $40 | $31.20 | +28.21% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $30.30 | +25.41% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $75.85 | -6.39% | 2 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | n/a | $72.86 | - | 2 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $65.57 | +64.71% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $223.41 | +21.30% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $15.28 | +129.06% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $332.61 | +27.48% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $59.95 | +100.17% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $20.18 | +420.32% | 7 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $10.66 | +143.90% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $5.50 | +2,081.82% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $29.91 | +903.01% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $31.11 | +86.44% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $482.42 | -59.37% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $2.27 | +4,217.18% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $150.52 | -60.14% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $46.45 | +39.94% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $17.88 | +308.28% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $21.75 | +258.62% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.55 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.48 | +407.08% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $12.22 | +71.85% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $53.70 | -70.20% | 1 | May 7, 2020 |
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $31.20
Upside: +28.21%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $30.30
Upside: +25.41%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $75.85
Upside: -6.39%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $72.86
Upside: -
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $65.57
Upside: +64.71%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $223.41
Upside: +21.30%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $15.28
Upside: +129.06%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $332.61
Upside: +27.48%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $59.95
Upside: +100.17%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $20.18
Upside: +420.32%
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $10.66
Upside: +143.90%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.50
Upside: +2,081.82%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $29.91
Upside: +903.01%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $31.11
Upside: +86.44%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $482.42
Upside: -59.37%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $2.27
Upside: +4,217.18%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $150.52
Upside: -60.14%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $46.45
Upside: +39.94%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $17.88
Upside: +308.28%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $21.75
Upside: +258.62%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.55
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.48
Upside: +407.08%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $12.22
Upside: +71.85%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $53.70
Upside: -70.20%